Glutathione and oxidative stress: a large literature that does not say what it is sold for

Of everything in this catalogue, glutathione has the biggest published literature and the widest gap between that literature and what the compound is marketed for. Tens of thousands of papers measure it. Very few of them are about supplying it from outside the cell, and the ones that are mostly report how hard that is.

What the molecule is

Glutathione is a tripeptide of glutamate, cysteine and glycine. It is not assembled on a ribosome and its first bond is not an ordinary peptide bond: the glutamate is joined through its side-chain carboxyl in a gamma-glutamyl linkage, which is why this catalogue's spec table prints no one-letter sequence for it. Writing "ECG" would state a structure the molecule does not have.

It is made inside the cell in two ATP-dependent steps, by glutamate-cysteine ligase and then glutathione synthetase, and cysteine availability is normally the limiting input; Lu's review is the standard account of that pathway (PMID 22995213). Intracellular concentrations are millimolar — high enough that glutathione is better described as a redox buffer than as a signalling molecule. The ratio of reduced glutathione to its oxidised disulphide form is one of the most-used readouts of cellular redox state in biochemistry.

Its jobs are specific rather than general. Glutathione peroxidases use it to reduce hydrogen and lipid peroxides. Glutathione S-transferases conjugate it onto electrophiles so they can be exported. The gamma-glutamyl cycle, worked out largely by Alton Meister's laboratory, recovers the constituent amino acids outside the cell (PMID 3053703). "Antioxidant" is a true but lazy description of a molecule that is mostly an enzyme substrate.

The one place this biology is settled clinical practice

Paracetamol overdose. The toxic metabolite is detoxified by glutathione conjugation, hepatic stores are depleted, and the licensed antidote is N-acetylcysteine — which works by supplying cysteine for the liver to synthesise its own glutathione.

Read what that means. The medicine with an approved indication resting on glutathione biology is the precursor, not the tripeptide, and that choice was made on pharmacokinetic grounds.

The delivery problem, which is well documented

This is the part of the literature a buyer should read first.

Witschi and colleagues examined the systemic availability of oral glutathione in 1992 and reported that plasma concentrations were not meaningfully raised by what was given (PMID 1362956). That paper is thirty-four years old and still gets cited, because the obstacle it identified is structural: the intact tripeptide is efficiently hydrolysed by gamma-glutamyl transpeptidase at the surface of cells lining the gut and elsewhere, and what reaches the circulation is largely its constituent amino acids.

Later work is mixed rather than uniformly negative, and it is worth stating that honestly. Richie and colleagues ran a randomised controlled trial of longer oral supplementation and reported increases in body stores of glutathione in blood compartments (PMID 24791752). Allen and Bradley examined oral supplementation against systemic oxidative-stress biomarkers in volunteers and reported no change in the markers they measured (PMID 21875351). A raised pool and an unchanged functional readout are not the same result, and the field has not reconciled them.

The clearest human data comes from the indirect route. Supplying glycine and N-acetylcysteine as precursors — the GlyNAC work — has been examined in randomised trials in older adults, with glutathione concentrations among a wide panel of measured outcomes (PMID 35975308). Those trials are small and the endpoint panel is broad enough that readers should check the pre-specification themselves. But they test the precursor strategy, not the tripeptide one.

Skin lightening, which is what most of the demand is actually for

A large share of the glutathione market, and essentially all of the injectable market, is cosmetic. The mechanistic rationale is real as far as it goes: glutathione participates in the switch between eumelanin and pheomelanin synthesis.

The clinical evidence does not follow from that. A 2025 systematic review assessed glutathione as a skin-lightening agent and in melasma and described a body of small, short, heterogeneous trials (PMID 39444151). Regulators have been blunter than the reviews: the United States FDA has warned about unapproved injectable skin-lightening products, and the Philippine FDA issued a public advisory specifically against intravenous glutathione used for skin lightening, citing adverse events reported there. Those are regulatory statements rather than trial results, and they are part of the record.

Where the evidence stops

It is approved nowhere for the things it is sold for. Not for ageing, not for detoxification, not for skin lightening, not as a therapy for any condition, by Health Canada or the FDA. It is permitted as a supplement ingredient in some markets, which is a different legal category from an approved medicine and carries no efficacy finding.

"Deficiency" needs a measurement. Lower glutathione is reported in ageing and in many conditions, which is a correlation in a biomarker and not a demonstration that raising it changes anything.

The bioavailability question is not closed in its favour. It is the central open question, it has been open since 1992, and the trials that address it directly are few.

For another endogenous cofactor with the same structural problem — enormous basic literature, thin evidence for supplying it from outside — see NAD+ and mitochondrial research, which is supplied here as NAD+. For the skin literature where a copper peptide's claims are tested against controlled work, see GHK-Cu and photoaging. Nothing here is medical, dosing, or therapeutic guidance.

The arithmetic, which is the part that is definite

No amount is given here and none is implied. Concentration is simple: a 1500 mg vial reconstituted with 10 mL of diluent gives 150 mg/mL, and the same vial with 15 mL gives 100 mg/mL. That is division, and it is the only number on this page that is not contested somewhere in the literature.

Glutathione is supplied here as Glutathione. Janoshik-verified by HPLC with mass-spec identity confirmation; 100% synthetic. The measured purity for each lot is stated on its product page. For laboratory research use only.

Common questions

If glutathione is so central to cell biology, why is the supplementation evidence weak? Because being central and being supplementable are unrelated properties. The cell makes it where it is needed, regulates its own synthesis, and breaks down what arrives from outside. Importance does not imply a delivery route.

Is oral glutathione useless then? The trials disagree. Some report a raised pool, at least one reports no change in function, and all are small. Anyone claiming the question is settled either way is overstating their evidence.

Why is it the compound in this catalogue whose claims are furthest from its evidence? Because the basic biology is so well established that it is easy to borrow authority from it. A sentence about glutathione's role in redox homeostasis is true; attaching it to a vial implies a finding nobody has published.

Is it legal to buy in Canada? It is sold here as a research chemical, for laboratory use only. It is not an approved drug in Canada and is not sold for human use.

Selected Research References

1. Lu SC. Glutathione Synthesis. Biochimica et Biophysica Acta. 2013;1830(5):3143-3153. pubmed.ncbi.nlm.nih.gov/22995213
2. Meister A. Glutathione Metabolism and Its Selective Modification. Journal of Biological Chemistry. 1988;263(33):17205-17208. pubmed.ncbi.nlm.nih.gov/3053703
3. Witschi A, Reddy S, Stofer B, Lauterburg BH. The Systemic Availability of Oral Glutathione. European Journal of Clinical Pharmacology. 1992;43(6):667-669. pubmed.ncbi.nlm.nih.gov/1362956
4. Richie JP Jr, Nichenametla S, Neidig W, et al. Randomized Controlled Trial of Oral Glutathione Supplementation on Body Stores of Glutathione. European Journal of Nutrition. 2015;54(2):251-263. pubmed.ncbi.nlm.nih.gov/24791752
5. Allen J, Bradley RD. Effects of Oral Glutathione Supplementation on Systemic Oxidative Stress Biomarkers in Human Volunteers. Journal of Alternative and Complementary Medicine. 2011;17(9):827-833. pubmed.ncbi.nlm.nih.gov/21875351
6. Kumar P, Liu C, Suliburk J, et al. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. Journals of Gerontology Series A. 2023;78(1):75-89. pubmed.ncbi.nlm.nih.gov/35975308
7. Sarkar R, Yadav V, Yadav T, et al. Glutathione as a Skin-Lightening Agent and in Melasma: A Systematic Review. International Journal of Dermatology. 2025;64(6):992-1004. pubmed.ncbi.nlm.nih.gov/39444151

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.